Shots:

• The US FDA has approved Audenz (Influenza A (H5N1) monovalent vaccine- adjuvanted) to protect patients aged ≥6mos. against influenza A
• The novel vaccine combines two technologies i.e- MF59 adjuvant and cell-based antigen manufacturing. The MF59 adjuvant and formulated prefilled syringes used in the Audenz vaccine- produced in the facility at Holly Springs- NC- supported by its partnership with the BARDA
• Audenz is the first and only adjuvanted- cell-based pandemic vaccine- designed to provide active immunization against the influenza A virus H5N1 strain and has received FDA’s FT designation to prevent pandemic influenza caused by A (H5N1) virus in Dec’2015

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: WRAL Techwire